Structural Biology of the TGFβ Family

Overview

Journal Exp Biol Med (Maywood)

Specialty Biology

Date 2019 Oct 10

PMID 31594405

Citations 20

Authors

Erich J Goebel

Kaitlin N Hart

Jason C McCoy

Thomas B Thompson

Affiliations

Soon will be listed here.

Citing Articles

Intestinal Fibrogenesis in Inflammatory Bowel Diseases: Exploring the Potential Role of Gut Microbiota Metabolites as Modulators.

Cicchinelli S, Gemma S, Pignataro G, Piccioni A, Ojetti V, Gasbarrini A Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675450 PMC: 11053610. DOI: 10.3390/ph17040490.

Cholesterol modulates type I/II TGF-β receptor complexes and alters the balance between Smad and Akt signaling in hepatocytes.

Chaudhary R, Goodman L, Wang S, Asimakopoulos A, Weiskirchen R, Dooley S Commun Biol. 2024; 7(1):8.

PMID: 38168942 PMC: 10761706. DOI: 10.1038/s42003-023-05654-9.

Characterization of the molecular mechanisms that govern anti-Müllerian hormone synthesis and activity.

Stocker W, Howard J, Maskey S, Luan H, Harrison S, Hart K FASEB J. 2023; 38(1):e23377.

PMID: 38133902 PMC: 10926428. DOI: 10.1096/fj.202301335RR.

Variants Can Associate with Non-Syndromic Congenital Heart Disease without Aortopathy.

Alaamery M, Albesher N, Alhabshan F, Barnett P, Salim Kabbani M, Chaikhouni F J Cardiovasc Dev Dis. 2023; 10(11).

PMID: 37998513 PMC: 10672196. DOI: 10.3390/jcdd10110455.

TGF-β signaling in health and disease.

Massague J, Sheppard D Cell. 2023; 186(19):4007-4037.

PMID: 37714133 PMC: 10772989. DOI: 10.1016/j.cell.2023.07.036.

References

Wang R, Zhu J, Dong X, Shi M, Lu C, Springer T . GARP regulates the bioavailability and activation of TGFβ. Mol Biol Cell. 2012; 23(6):1129-39. PMC: 3302739. DOI: 10.1091/mbc.E11-12-1018. View

Wu J, Krawitz A, Chai J, Li W, Zhang F, Luo K . Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling. Cell. 2002; 111(3):357-67. DOI: 10.1016/s0092-8674(02)01006-1. View

Shi Y, Hata A, Lo R, Massague J, Pavletich N . A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997; 388(6637):87-93. DOI: 10.1038/40431. View

Gao Y, Vincent D, Davis A, Sansom O, Bartholin L, Li Q . Constitutively active transforming growth factor β receptor 1 in the mouse ovary promotes tumorigenesis. Oncotarget. 2016; 7(27):40904-40918. PMC: 5173031. DOI: 10.18632/oncotarget.10149. View

Brunet L, McMahon J, McMahon A, Harland R . Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science. 1998; 280(5368):1455-7. DOI: 10.1126/science.280.5368.1455. View

Zhang J, Huang Y, Qiu L, Nickel J, Sebald W . von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J Biol Chem. 2007; 282(27):20002-14. DOI: 10.1074/jbc.M700456200. View

Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, Ten Dijke P, Heldin C . Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem. 1997; 272(44):28107-15. DOI: 10.1074/jbc.272.44.28107. View

Greenwald J, Vega M, Allendorph G, Fischer W, Vale W, Choe S . A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol Cell. 2004; 15(3):485-9. DOI: 10.1016/j.molcel.2004.07.011. View

Keller S, Nickel J, Zhang J, Sebald W, Mueller T . Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol. 2004; 11(5):481-8. DOI: 10.1038/nsmb756. View

10.

Ge G, Hopkins D, Ho W, Greenspan D . GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol. 2005; 25(14):5846-58. PMC: 1168807. DOI: 10.1128/MCB.25.14.5846-5858.2005. View

11.

Boesen C, Radaev S, Motyka S, Patamawenu A, Sun P . The 1.1 A crystal structure of human TGF-beta type II receptor ligand binding domain. Structure. 2002; 10(7):913-9. DOI: 10.1016/s0969-2126(02)00780-3. View

12.

Liu F, Ventura F, Doody J, Massague J . Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol. 1995; 15(7):3479-86. PMC: 230584. DOI: 10.1128/MCB.15.7.3479. View

13.

Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T . Latent TGF-β structure and activation. Nature. 2011; 474(7351):343-9. PMC: 4717672. DOI: 10.1038/nature10152. View

14.

Baardsnes J, Hinck C, Hinck A, OConnor-McCourt M . TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs. Biochemistry. 2009; 48(10):2146-55. PMC: 2801812. DOI: 10.1021/bi8019004. View

15.

Kotzsch A, Nickel J, Seher A, Heinecke K, van Geersdaele L, Herrmann T . Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J Biol Chem. 2007; 283(9):5876-87. DOI: 10.1074/jbc.M706029200. View

16.

Le V, Iacob R, Tian Y, McConaughy W, Jackson J, Su Y . Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation. EMBO J. 2018; 37(3):384-397. PMC: 5793799. DOI: 10.15252/embj.201797931. View

17.

Mace P, Cutfield J, Cutfield S . High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: implications for ligand binding. Biochem Biophys Res Commun. 2006; 351(4):831-8. DOI: 10.1016/j.bbrc.2006.10.109. View

18.

Lerch T, Shimasaki S, Woodruff T, Jardetzky T . Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem. 2007; 282(21):15930-9. DOI: 10.1074/jbc.M700737200. View

19.

Klages J, Kotzsch A, Coles M, Sebald W, Nickel J, Muller T . The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding. Biochemistry. 2008; 47(46):11930-9. DOI: 10.1021/bi801059j. View

20.

Marlow M, Brown C, Barnett J, Krezel A . Solution structure of the chick TGFbeta type II receptor ligand-binding domain. J Mol Biol. 2003; 326(4):989-97. DOI: 10.1016/s0022-2836(03)00023-8. View